Table 2.
Clinical Demographics and Hospital Course for Patients Transfused CCP.
| General Clinical Demographics | |
|---|---|
| Age (mean ± SD) | 60.2 ± 13.7 years (median 61, range 22–89 years) |
| Gender (N (% total group)) | Male 22 (50%) |
| Female 22 (50%) | |
| ABO Blood Type (N (% total group)) | A 16 (36%) |
| B 1 (2%) | |
| AB 2 (5%) | |
| O 25 (57%) | |
| Rh (N (% total group)) | Positive 36 (82%) |
| Negative 8 (18%) | |
| Admission and Hospitalization Details | |
| Residence Prior to Admission | Home (self-care) 35 (80%) |
| Skilled Nursing Facility 9 (20%) | |
| Duration of Symptoms Prior to Admission (mean ± SD) | 8.3 ± 5 days (median 7, range 2–28 days) |
| COVID-19 Disease Status on Admission | Severe Disease 36 (82%) |
| Life-Threatening Disease 8 (18%) | |
| Hospital Course of COVCID-19 | |
| Escalation of Oxygen Requirements | YES 16 (36%) |
| NO 18 (41%) | |
| Escalation on admit 10 (23%) | |
| (Escalation within 24 hours of Admission) | |
| Admission to Escalation in days (mean ± SD) | 3.9 ± 3.0 days (median 3.0, range 1–10 days) |
| Intubation/Mechanical Ventilation | YES 17 (39%) |
| NO 27 (61%) | |
| Duration of Mechanical Ventilation in days (mean ± SD, excludes 5 deaths while ventilated) | 10.5 + 8.4 days (median 7, range 1 −24 days) |
| Admission to Respiratory Improvement in days (mean ± SD) | 7.9 + 5.4 days (median 6.0, range 1–23 days) |
| Other Treatments rendered | Hydroxychloroquine 10 (23%) |
| Systemic Steroids 22 (50%) | |
| Remdesivir 22 (50%) | |
| Antibiotics 27 (67%) | |
| Vassopressors 14 (32%) | |
| Outcome/Discharge Details | |
| Length of Stay (mean ± SD) | 15.8 ± 11.3 days (median 10.5, range 3–40 days) |
| Discharge Status | Home Self-care 23 (52%) |
| Skilled Nursing Facility 11 (25%) | |
| Rehab. Facility 3 (7%) | |
| DIED (in-hospital death) 7 (16%) | |
| Oxygen Requirements at Discharge | None 28 (64%) |
| NC O2 7 (16% | |
| Died 7 (16%) |